PPARG and hypertriglyceridemia: Therefore, using a PPARδ specific ligand, GW0742, can activate the protective effects from hypertriglyceridemia and insulin resistance as what PPARα and PPARγ do but alternatively prevents the sequel of edema and fluid retention induced by PPARγ [14, 18].